NEW YORK (GenomeWeb) The discovery of bacterial CRISPR systems has created a cottage industry of researchers and biotechnology companies hoping to use the genome-editing method to cure disease or create better medications for a variety of illnesses. But there have been problems along the way many naturally occurring CRISPR proteins are unsuitable for use in human cells, either because they don't work at all, work very ineffectively, or create off-target effects that end up causing more problems than they solve.

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.

*Before your trial expires, well put together a custom quote with your long-term premium options.

Here is the original post:

MilliporeSigma's Proxy-CRISPR Tech Aims to Increase Usability of Native CRISPR Proteins - GenomeWeb

Comments are closed.